clinical with now Thanks, Steve. program. update give CBXXXX programs, of our I’ll a R&D brief our beginning
please. slide, Next
mitochondria candidate based So clinical stage now no therapeutic, a resuming NASH lead year. potential or study and study this a as treatment is in since in been Phase been of of Ia completed, Phase testing the safety significant CohBar’s The tolerability the June Ia/Ib has and of observed obesity. currently have CBXXXX, issues
ascending The the use follow-on the adults Phase the this single tolerability of designed Ia study Phase conventional placebo-controlled assessment healthy part identify Ib stage. multiple dose a ascending was pharmacokinetics in dose of and in safety, for to double-blind appropriate most dose,
body will evaluation subjects placebo-controlled effects of is dose Now CBXXXX the assess and relevant biomarkers of on the potential liver double-blind disease. NASH, are the Phase obese be Ib in part of chosen CBXXXX that to NAFLD various study and with a obesity to weight fat, and of the designed metabolic
we database of that of the the of after as activity function The subjects. will is is of more At this study and study still from when analysis on is completion occur mid-XXXX. time, study somewhere only Phase the blinded, will study un-blinded Ib we of clarity the finally the rates, locked, anticipate is top-line availability data progresses. and the of currently recruiting the Phase The in be data stage. stages timing both will recruitment a have exact stage The Ib study an
you at updates update subjects, planned, obese the on last would milestones. expect to study and stated progress we we dosing of NAFLD study If the provide call, goes the such in next call. will likely on we quarterly significant the the the next milestone on as be the progress of on Now the as investor end our last
that the shared release has novel from fatty efficacy presents and action with mechanism for opportunity novel fat preclinical previously different have data mechanisms. other models of of the regulation involving a which demonstrated both cells, a and acid in CBXXXX of for an animal have We combination obesity. XXXX, NASH of CBXXXX that mechanism drugs
shared of it’s some PPAR are XX% data with CBXXXX with agonist, in to diabetes. that to synergy the slides. note also good And patients We the used diabetic. of commonly also on previously type of data GLP-X NASH X briefly showing cover of We’ll classes X drugs historical few treat about next this and gamma
Next slide, please.
review the the CBXXXX. after in in the high-level reduction CBXXXX on Score, observed STAM dosing a in NAF, treatment the DIO of of mouse model mice, XX high-fat of of days some see body NASH. data In published on significant Activity weight efficacy middle, is maintained in a you diet. the the obese, NAFLD of induced the days reduction preclinical can this or XX on significant Showing left, So the after diet
seen in And decrease can in DIO in you liver white a on deposits see microscope. versus the resulting of number of the less fat the under selective fat clear in these right, reduction mice the in lean
slide, Next please.
a synergistic previously the mice, a on the mechanism CBXXXX of a in of study different disclosed DIO for XXXX liraglutide, effects action. with some of approved we Here, synergy showed peptide of review agonist and mass In weight alone. GLP-X the with proportion data the compared of type liraglutide After in days body and the produced in the body and diabetes treatment the loss of combination XX XXXX X treatment, greater of a obesity. reduction of fat liraglutide to
be XX the days. with of greatly complementary other fat result animals GLP-X setting liraglutide results use a the for on already completely deposits many these fat On combination also agonist. animals still like from alone, see at medications there of in are where present, mechanisms. potential are can XXXX and right, you there synergy And content. This of with while using suggests livers in reduced the could drugs X different This XXXX the liver patients images white given
Next slide, please.
of from regulation a healthy is which a in release cells, key abdominal flow cells. generates free of of fats, cells schematic fat fat fat shows slide free the in from and acid regulates fatty metabolism liver, NASH, lipolysis in bloodstream. this action fatty high process Now the the involves of which stored the proposed muscle of insulin CBXXXX acids people, insulin regulator level setting In mechanism of into of that then and
resulting excess uncontrolled cascade fat inflammation, fibrosis. in the the of the a tissue steatosis. known sensitive damage to fat lipolysis. starts accumulation Excess cells metabolism with subjects abdominal the in fat and free leading acids of fatty and to a a in insulin, the This fat leads become then in cells hepatic from liver, events of dysregulated However, less blood into condition as NAFLD, can to lipotoxicity, cause release which and liver
the foundational insulin CBXXXX acts the in cells, fatty effect It into of specific excess in of among observations enhances and acids the accumulation models. synergy flow of lead that with to the action of drugs NASH. to explain animal in and liver under our drug NASH This other investigation currently appears previous on mechanism free appears to blocking NASH. for reducing event the fat be of decreasing can unique some the fat lipolysis the thereby on of blood, the Now mechanisms
While this efficacy in mechanism the and the of action be the setting of CBXXXX by NASH. it the one CBXXXX provide a exerted animals basis does in in only potential may not body, for of
please. slide, Next
talk note peptide It’s important that I’ll family mitochondria not their new rest CohBar’s broadening that efforts own and the based about determines all related and therapeutic our distinct not has their assessment potential. of Now peptides additional to our pipeline of and candidates, structural therapeutic identifying structurally MOTS-c of or these towards Each research – properties, are activity. its to that CBXXXX.
made that progress our shared call. progress and of areas, significant We in main last some recently X we’ve on
of cover animal I’ll cells biomarkers effects idiopathic model fibrosis for fibrosis a diseases human which in of an fibrosis. model in of where The setting novel decreased peptide analog, the – promising we’ve pulmonary anti-fibrotic and first culture in area a shown decreased fibrotic is in
of area to cancer cells cells second an that in progress peptide immune analogs novel the immuno-oncology The we’ve cancer, to model. number is vitro, a what where identified referred enhance is ability kill in of human of as
a progress peptides diabetes of third type in research, animal glucose models with beneficial setting identified we regulation novel The effects recently area in diabetes. on of of the of is where family X
the included interaction family apelin discovery at receptor. important between a details shared in peptides of receptor, American surface of Diabetes this peptides key these We cell June. the our new that of called and an And Association meeting
process The vitro process for iterative, off-target metabolic factors stability, optimization in optimizing synthesizing of protection. these all and improved the of properties, it in for areas. chemical and potency and numerous vivo we’re of cycle physical analogs of discovery potential including in synthesis chemical activity peptides assessing Now ease and for stability, potential the the X in IP requires is them a
an candidate appropriate timing to reach number factors. competitive the of and the clinical of peptide market regulatory The and until opportunity, cycle involves concept, a indication final a numerous factors risks prove such we intended need, also repeats as a and for optimized landscape, as selection for the unmet other pathways, specific the our reimbursement an clinical clinical profile a indication the drug
next and we is candidate will candidate guarantee when This XXXX. cannot our our a although be Now is our clinical CohBar, priority drug drug goal identify clinical next for in high identified. to
Next slide, please.
So and fibrotic diseases, kidney disease-related and NASH lung, We inflammation with peptides previously a new of pulmonary cell-based in of in but scarring the data and fibrosis. tissues to a including Fibrosis underlies the a and biomarkers age-related liver, heart, progression process in area of CohBar’s key we of is X, significant peptide identification like showed normal also fibrosis tissue the the diseases. of of response number age antifibrotic initially decrease shared from injury the MBT potential. other in produced model fibrosis
number in vehicle the some again, In bleoMycin then to an study, this to for weeks examined were of lungs well-established objective normal were see, tissue grades in by that scale very mice a and On similar lung with microscopy, damage control were with fibrosis. vivo on X extent induce XX changes response the lung the idiopathic not fibrotic based compared of this data to scored and receive changes. human for Ashcroft dosed pulmonary disease, MBT After or called treated was bleomycin. you a did which the days, Animals with fibrosis using the fibrosis. slide, model animals mouse of scale, peptide X and lung CohBar
that – it’s on Animals X days. fibrosis, left, can the on with In vehicle treated scale. about controlled XX the had the you significant top left see on figure top reaching Ashcroft the
once-daily with Ashcroft CohBar had peptide fibrosis lower treated those While significantly a score.
see lungs visually of the also bottom of can photo the on slide. the that You in the micrographs
of far of bleomycin. left, effects did receive In the with see On a the followed lungs control. induction, are days a animal,that Bleomycin by middle, there vehicle treatment you not of the normal XX
thickening is of and significant some here with lung of There of formation damage tissue are marked of knots, which the fibrous fibrotic arrows. red the appearance with many
our models for model. CohBar’s a animals exposed lung protection, of vitro then treated in an peptide, now XX evaluation activity. However, days additional confirmatory preliminary into data conducting expanded efficacy to anti-fibrotic efficacy These indicating show clear direct to other fibrosis, signal in and in studies fibrotic disease bleomycin in we’ve And there translation of is with we’re animal a and diseases.
shows same the fibrosis X reduction XX study. data lung This the present lung cells bleomycin in case, lung please. were days this induced Next in slide inflammatory previous slide, see on mouse based treatment. fluid some of MBT the we In the the number from that in decrease of significant number produced of after inflammation that a
in we And slide, into Next slide, study data please. these this animal perspective. put
IPS MediciNova currently study On slow the for NASH. and drug the conducted to results After XX you studies reduction study the same by same left, the X in study right. reduction very similar of the can fibrosis days the site MBT clinical a lung on which drug see The mouse of MN-XXX, that is design. fibrosis of a number see with score Phase MediciNova’s Japan is using was II in produced in we treatment, the
in confirmatory number diseases. Now still include studies the as in is opportunities for these other inflammatory preliminary tissue optimization. Ongoing MBTs process diseases. evaluation fibrotic MBT lung of But of animal range data for of also the and a CohBar’s studies fibrotic suggest and potential X treatments additional in models
Next slide, please.
Recently, immune kill enormous from boost vitro this we PhenoVista approaches field have CRO that data treatment of in our to This there the cells recognize as to see our or approach So slide, by using that novel cancer immunotherapy enhances a kill this ability own to own known of advances cells In in an and invading our cancer the reviews cells. example slide turning model partner, run CohBar area been immuno-oncology of cancer immuno-oncology. A efforts our the cells. ability in an of cancer. external peptide immune Biosciences. preliminary the
cells, grown cells, include, Killer a response. called induce study, called cells blood immune peripheral Natural immune blood a like melanoma mononuclear lines human to are are In this tumor human these immune The SK-Mel-XX, cells, cells, for standard T cells, line. B human been an cell cells with PBMCs, have together stimulated example, cell which
Activated cancer PBMCs cells. attack the
our particular we presence look enhancement number as potential the killing the the cells for response cancer can more a cancer stimulated the MBT when of reflected we their microscopy, the saw this Now of We in in cancer significant stains cell incubate death. presence highly on effect live techniques. specific of and case, this of in peptide, the same of immune imaging cells measure CohBar specific we cells by in increase X. any In number peptide using
On PBMCs cytoplasm designed all using stains the the in see left, cells, you cells green. Cancer and labeled of in the the the blue XX cells of hours, to at specifically images labeling show just or cells representative of nuclei cancer
was when in see, was cells the there can cancer a decrease peptide substantial providing You present.
data, course, in Now evaluating forward are, these of animal models these early of with and now studies additional we’re cancer. peptides and moving
Next slide, please.
the family diet of human CohBar. induced a in discovery Peptide of X Francisco June. beneficial a CBXXXX, model diabetes. – scientific So of some treatments reported published in diabetes. type the of novel review a family of was effects is or new San third of Mitochondrial-Encoded sessions type American summary obese, ongoing This the Diabetes potential a that the the was analogs meeting discovered CohBar a peptide data presented area This evaluation by novel we’ll in slide peptides our human mice, of We DIO at of X of had that peptides as is for briefly XXth the of annual Association
fat mice. loss DIO to mass produced placebo compared the analogs of in CBXXXX significant body loss Now and weight
also ADA glucose peptides selective these presented addition, one tolerance. discovery receptor, with apelin of the receptor. our a these of very improved peptides In poster interaction The specific
expressed energy key many novel kidney, by is that’s the type cellular potential number heart, different a others of in fluid but also role disease in liver function a opens of to in peptide tissue, other diabetes door been processes. the and interaction cardiovascular tissues, a has Now in metabolism, apelin natural apelin and utility apelin X explored lung, the these receptor function, peptides and This and play settings. to brain. of homeostasis including adipose metabolic And other regulating appears
This our current high-level our Next expanding slide process, of NASH R&D a MBTs. analogs where candidate, clinical number that overview final for cancer entering and with diseases, optimization ongoing an MBT X These its is potential of obesity. include now programs studies. clinical stage and are is for Phase of slide, fibrotic promising list to in of testing CBXXXX, both now activity relevant first please. effects Ib animal Behind the is new diabetes. and indications are showing type a the
back the Steve. I’ll And with that, turn to call
